Literature DB >> 16026411

Gonadotrophin-releasing hormone-antagonist luteolysis during the preceding mid-luteal phase is a feasible protocol in ovarian hyperstimulation before in vitro fertilization.

Barbro E Fridén1, Lars Nilsson.   

Abstract

BACKGROUND: The aims of this study were to investigate whether a high dose of gonadotrophin-releasing hormone antagonist during the preceding luteal phase yields satisfactory luteolysis and downregulation prior to ovarian hyperstimulation in an in vitro fertilization program.
METHODS: The treatment protocol was designed as a prospective pilot study in IVF units at two university hospitals. Fifty-one patients with documented poor or normal response to ovarian stimulation underwent 57 treatment cycles. Treatment consisted of 3 mg gonadotrophin-releasing hormone antagonist (cetrorelix) given during the preceding mid-luteal phase as gonadotrophin-releasing hormone-receptor inhibition before ovarian stimulation with follicle-stimulating hormone.
RESULTS: All women experienced menstrual bleeding within 2-3 days after the injection of 3 mg cetrorelix. Follicle hormone stimulation could subsequently commence in all cycles. All but three patients developed growing follicles and underwent oocyte retrieval. Seventy-five percent of started cycles reached transfer of one or two good-quality embryos.
CONCLUSIONS: A single high-dose gonadotrophin-releasing hormone antagonist given during the preceding luteal phase presents a new and feasible protocol to initiate controlled ovarian hyperstimulation in an in vitro fertilization program.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16026411     DOI: 10.1111/j.0001-6349.2005.00730.x

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  3 in total

1.  GnRH analogues in the prevention of ovarian hyperstimulation syndrome.

Authors:  Pilar Alama; Jose Bellver; Carmen Vidal; Juan Giles
Journal:  Int J Endocrinol Metab       Date:  2013-04-01

2.  Cetrotide administration in the early luteal phase in patients at high risk of ovarian hyperstimulation syndrome: A controlled clinical study.

Authors:  Ya-Qin Wang; Nan Yu; Wang-Min Xu; Qin-Zhen Xie; Wen-Jie Yan; Geng-Xiang Wu; Jing Yang
Journal:  Exp Ther Med       Date:  2014-10-06       Impact factor: 2.447

3.  Gonadotropin releasing hormone antagonist administration for treatment of early type severe ovarian hyperstimulation syndrome: a case series.

Authors:  Dayong Lee; Se Jeong Kim; Yeon Hee Hong; Seul Ki Kim; Byung Chul Jee
Journal:  Obstet Gynecol Sci       Date:  2017-09-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.